Stocktoria

BRISTOL MYERS SQUIBB CO BMY

NYSE · XNYS · stock · Pharmaceutical Preparations
Chart by TradingView
7/9
Piotroski F — financial health
Altman Z″ — distress risk
71.5%
Dividend payout · stretched

Financials (annual, from 10-K)

FYRevenueNet incomeGross profitFree cash flowEquity
2025$48.2B$7.1B$12.8B$18.5B
2024$48.3B-$8.9B$13.9B$16.3B
2023$45.0B$8.0B$12.7B$29.4B
2022$46.2B$6.3B$11.9B$31.1B
2021$46.4B$7.0B$15.2B$35.9B
2020$42.5B-$9.0B$30.7B$13.3B$37.9B

Recent insider activity (Form 4)

InsiderRoleDateActionSharesPrice
Haller Julia Adirector2026-06-15Option exercise20,460$53.76
Short Bartie WendyEVP, Corporate Affairs2026-06-03Option exercise8,040
Short Bartie WendyEVP, Corporate Affairs2026-06-03Tax withheld3,876$54.72
Lenkowsky AdamEVP, Chief Commercial Officer2026-05-01Option exercise1,373
Lenkowsky AdamEVP, Chief Commercial Officer2026-05-01J203
Lenkowsky AdamEVP, Chief Commercial Officer2026-05-01Tax withheld599$58.22
Shanahan KarinEVP, Chief Supply Chain & Ops2026-04-01Option exercise3,307
Shanahan KarinEVP, Chief Supply Chain & Ops2026-04-01Tax withheld1,692$61.73

Why these scores methodology →

Piotroski F-score: 7/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: n/a

Not applicable (financials/insurer or missing inputs).

Source: SEC EDGAR filings · CIK 0000014272 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.